Pharmacokinetics,Safety and Efficacy of Voriconazole in Pediatric Patients: An Update

Opportunistic invasive fungal infections are important infectious complications in severely immunocompromised children with hematological malignancies and/or hematopoietic stem cell transplantation, and are causes of considerable morbidity and mortality. Voriconazole is a broad-spectrum, second generation antifungal triazole with activity against yeast and filamentous fungi and first line indications against invasive aspergillosis and invasive candidiasis. While the compound has been approved in children and adolescents for several years, the dose finding in this population is ongoing and data on safety and efficacy continue to be accrued. The purpose of this article is to provide an update on the pharmacokinetics, safety and efficacy of voriconazole in pediatric patients.